Ligand Pharmaceuticals (LGND) Shares Outstanding (Diluted Average) (2010 - 2026)
Ligand Pharmaceuticals' (LGND) quarterly Shares Outstanding (Diluted Average) came in at $19.9 million in Q1 2026, up 3.61% year-on-year from $19.2 million in Q1 2025, and down 2.03% quarter-over-quarter from $20.3 million in Q4 2025.
Ligand Pharmaceuticals (LGND) Shares Outstanding (Diluted Average) (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has disclosed Shares Outstanding (Diluted Average) across 17 years of filings, most recently posting $19.9 million for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $19.9 million, up 3.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.9 million (up 3.61% YoY), and the FY2025 annual result was $20.3 million, up 10.96% from the prior year.
- Shares Outstanding (Diluted Average) came in at $19.9 million for Q1 2026 at Ligand Pharmaceuticals, down from $20.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $20.3 million in Q4 2025 to a low of $16.8 million in Q1 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $18.0 million (2024), against an average of $18.3 million.
- Across the five-year window, Shares Outstanding (Diluted Average) fell 2.46% in 2022 and rose 10.96% in 2025, its largest moves.
- Ligand Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $16.9 million in 2022, then gained by 5.27% to $17.8 million in 2023, then gained by 3.0% to $18.3 million in 2024, then grew by 10.96% to $20.3 million in 2025, then slipped by 2.03% to $19.9 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $19.9 million (Q1 2026), $20.3 million (Q4 2025), and $20.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Ligand Pharmaceuticals | 5.47 Bn | 4.69 Bn | 48.45 Mn | 19.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.88 Mn |
| Dec 31, 2025 | 20.29 Mn |
| Sep 30, 2025 | 20.17 Mn |
| Jun 30, 2025 | 19.26 Mn |
| Mar 31, 2025 | 19.19 Mn |
| Dec 31, 2024 | 18.29 Mn |
| Sep 30, 2024 | 18.42 Mn |
| Jun 30, 2024 | 18.03 Mn |
| Mar 31, 2024 | 18.12 Mn |
| Dec 31, 2023 | 17.76 Mn |
| Sep 30, 2023 | 17.78 Mn |
| Jun 30, 2023 | 17.73 Mn |
| Mar 31, 2023 | 17.97 Mn |
| Dec 31, 2022 | 16.87 Mn |
| Sep 30, 2022 | 17.13 Mn |
| Jun 30, 2022 | 16.85 Mn |
| Mar 31, 2022 | 16.82 Mn |
| Dec 31, 2021 | 17.25 Mn |
| Sep 30, 2021 | 17.14 Mn |
| Jun 30, 2021 | 17.17 Mn |